Climb Bio, Inc. (CLYM) Stock

Climb Bio, Inc. (CLYM) is a Healthcare stock trading at $11.45 (as of 2026-06-18), with a market capitalization of $627.58M and a trailing P/E of -14.9. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Valuation — source: SEC EDGAR (first-party)
Price	$11.45
Market Cap	$627.58M
P/E Ratio	-14.9
EV / EBITDA	-10.8
Price / Book	4.42
Price / Sales	86.76
DCF Value (model)	$-18.69
DCF Upside vs Price	-263.2%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$8.32M
Net Margin	-719.1%
Return on Equity	-35.6%
Current Ratio	27.86
Revenue Growth (YoY)	2.3%
EPS Growth (YoY)	-42.5%
FCF Growth (YoY)	169.9%

Financial Health — source: SEC EDGAR
Altman Z-Score	42.15 (safe)

Valuation vs Sector & Industry
Stock P/E	-14.9
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-171.1%
vs Industry	-187.3%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	RA CAPITAL MANAGEMENT, L.P. ($77.41M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Aoife Brennan BCh MMSc
Employees	17
Country	US
IPO Date	2021-08-10

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.